DocumentRX-1656
Issued
Read2 min

FDA clears Roche's Wilserdly a month ahead of deadline

FDA clears Roche's Wilserdly a month early at $22,500 per month, the only oral SERD with proven adjuvant benefit; a second decision on earlier use is due by Nov. 30.

TAG T-7183 · 495 words on the filing

Roche breast cancer pill cleared by FDA
Roche breast cancer pill cleared by FDAHeungSoon / pixabay

Summary of findings

  • FDA approved Wilserdly about a month ahead of a Dec. 18 decision deadline.
  • List price is $22,500 per month, per RBC Capital Markets analysts.
  • Indication limited to ER-positive, HER2-negative breast cancer patients with ESR1 mutations.
  • A second FDA decision on an earlier setting is due by Nov. 30.
  • RBC estimates peak annual sales of up to $14 billion.

The FDA has approved Roche's oral SERD Wilserdly, roughly a month ahead of a Dec. 18 decision deadline, clearing the pill Roche expects to become its best-selling product.

Roche said Monday that U.S. regulators approved Wilserdly as part of a two-drug oral regimen for certain adults with ER-positive, HER2-negative breast cancer. The indication covers patients who relapsed during or after hormone therapy in the post-surgery adjuvant setting, and following hormone therapy in metastatic disease. Only patients with ESR1 mutations qualify.

A second FDA decision could arrive by Nov. 30, covering an earlier setting that would significantly expand access to treatment.

What does the approval change for launch planning?

Wilserdly carries a list price of $22,500 per month, comparable to similar breast cancer medicines, according to a Monday research note from RBC Capital Markets analysts. Roche did not immediately respond to a request for comment.

The drug belongs to the class of selective estrogen receptor degraders, oral agents drugmakers have long viewed as potential replacements for the decades-old injectable hormone therapy fulvestrant. The class now includes entries from Eli Lilly, AstraZeneca and Roche. All of them are cleared only for patients with ESR1 mutations, and several, including Roche's drug, have failed clinical trials testing first-line use.

"The key debate is not whether oral SERDs work, it's where they fit," Jefferies analyst Michael Leuchten wrote to clients in an October note.

Where does Wilserdly sit against the class?

Roche argues the drug differs from its competitors on one point: it has succeeded in multiple treatment lines. Monday's approval covers a setting where other oral SERDs already compete, but Wilserdly is the only member of its class so far to also prove beneficial in the adjuvant setting.

On a July conference call, Roche Pharmaceuticals head Teresa Graham said the data accumulated to date suggests the company has "about 80% of the market covered." RBC analyst Trung Huynh has matched that optimism, estimating earlier this year that Wilserdly could generate as much as $14 billion in peak annual sales, with much of that tied to earlier-line use.

Leuchten is more cautious. In October, he wrote that projections for oral SERDs in the adjuvant setting depend on how much "white space" remains after the expansion of CDK 4/6 inhibitors. The remaining opportunity "remains substantial, though likely narrower and more segmented than headline patient numbers imply," he wrote.

What do the label warnings mean for prescribing?

For now, Wilserdly will compete for share in more advanced disease. Its prescribing information carried warnings for a slow resting heart rate and potential damage to a developing fetus. RBC's Huynh noted those disclosures "were not expected," but the absence of a heart monitoring requirement still gives Wilserdly a potential edge over AstraZeneca's drug.

Monday's approval is "a key first step" for Roche, Huynh added. The Nov. 30 adjuvant decision will show how far that step reaches.

via BioPharma Dive (Source)

Share this article:

More from Olivia Hart

Olivia Hart

Show full bio

Senior reporter covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.

22 articles

Linked filings

  1. K-4971
  2. K-7275
  3. C-4460
  4. K-1653
  5. P-6323

« Previous filingNext filing »